Search Within

Grace Hettich

Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Biostatistics Service (6)
  2. Department of Medicine (6)
  3. Epidemiology and Biostatistics (6)
  4. Genitourinary Oncology Service (6)
  5. Solid Tumor Oncology Division (6)
  6. Weinberg Fellows (6)

More Groups

People
  1. Asia McCoy (6)
  2. Dean Bajorin (6)
  3. Gopakumar Iyer (6)
  4. Jonathan Rosenberg (6)
  5. Samuel Funt (6)
  6. Hikmat Al-Ahmadie (5)

More People

Years
  1. 2022 (1)
  2. 2021 (2)
  3. 2020 (1)
  4. 2019 (2)
Publications
  1. Journal of Clinical Oncology (5)
  2. Cancer Medicine (1)
Publishers
  1. American Society of Clinical Oncology (5)
  2. Wiley Blackwell (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: A multicenter, single-arm, phase II trial
    Journal Article

    Funt, S. A.; Lattanzi, M.; Whiting, K.; Al-Ahmadie, H.; Quinlan, C.; Teo, M. Y.; Lee, C. H.; Aggen, D.; Zimmerman, D.; McHugh, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial
    Meeting Abstract

    Funt, S. A.; Lattanzi, M.; Whiting, K.; Al-Ahmadie, H. A.; Quinlan, C.; Teo, M. Y.; Kamradt, J.; Khalil, M. F.; Ostrovnaya, I.; McCoy, A. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract
    Journal Article

    Sarfaty, M.; Whiting, K.; Teo, M. Y.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; Jungbluth, A. A.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract
    Meeting Abstract

    Sarfaty, M.; Ostrovnaya, I.; Teo, M. Y.; Iyer, G.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Keegan, N. M.; Funt, S. A.; Kania, B. E.; Iyer, G.; Clement, J. M.; McCoy, A. S.; Hettich, G.; Ziv, E.; Maher, C. A.; Nair, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save